Previous close | 0.0600 |
Open | N/A |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 48.00 |
Expiry date | 2024-05-31 |
Day's range | 0.0600 - 0.0600 |
Contract range | N/A |
Volume | |
Open interest | 1 |
DEERFIELD, Ill., May 29, 2024--Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis (HF HD). The study, "Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study," was prese
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Baxter...